Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection
David M. Margolis; A. Lisa Mukherjee; Courtney V. Fletcher; Evelyn Hogg; Debra Ogata-Arakaki; Tianna Petersen; David Rusin; Ana Martinez; John W. Mellors (Profiled Author: David M Margolis)
OBJECTIVE: We evaluated the safety, tolerability and antiretroviral activity of β-D-2,6-diaminopurine dioxolane (DAPD; amdoxovir) with or without mycophenolate mofetil (MMF) in HIV-1 infection following extensive antiretroviral therapy (ART). METHODS: Oral DAPD 500 mg twice daily with placebo or MMF 500 mg twice daily was added to failing ART. HIV-1 RNA viral load (VL) decline to week 2 was analyzed by intent-to-treat, using rank-based tests. Patients with VL decline > 0.5 log10 copies/ml at week 2 (virologic response, VR) optimized ART and continued therapy for up to 96 weeks. RESULTS: Forty adults with median VL 4.5 log10 copies/ml, median 184 CD4+ cells/μl, and a median of 6 nucleoside reverse transcriptase inhibitor (NRTI) mutations (range, 1-8) were randomized. Median VL reduction at week 2 was -0.26 log10 copies/ml (P < 0.0001). Response to DAPD/placebo (median -0.37 log10 copies/ml) was unexpectedly greater than to DAPD/MMF (median -0.23 log10 copies/ml), although this difference was not statistically significant (P = 0.59). MMF appeared to lower concentrations of DAPD and its metabolite dioxolane guanosine. Of 10 patients with VR (DAPD 7, DAPD/MMF 3), four persisted beyond week 24. VR was more frequent with ≤ 5 baseline NRTI mutations (P = 0.12) or < 4 thymidine-associated mutations (TAMs) without E44D or V118I (P = 0.08). Twenty-three patients received extended DAPD +/- MMF; five beyond week 24. Few adverse events were related to study medications. CONCLUSIONS: The addition of DAPD +/- MMF to failing therapy appears safe and well tolerated. DAPD had significant activity at week 2 (mean -0.35 log10) in heavily pretreated patients that was not augmented by MMF. © 2007 Lippincott Williams & Wilkins, Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
David A. Cooper; Roy T. Steigbigel; Jose M. Gatell; Jurgen K. Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N. Kumar; Joseph E. Eron; et al.New England Journal of Medicine. 2008;359(4):355-365.
Mary A. Albrecht; Ronald J. Bosch; Scott M. Hammer; Song-Heng Liou; Harold Kessler; Michael F. Para; Joseph Eron; Hernan Valdez; Marjorie Dehlinger; Davida KatzensteinNew England Journal of Medicine. 2001;345(6):398-407.
Daniel R. Kuritzkes; Ian Marschner; Victoria A. Johnson; Roland Bassett; Joseph J. Eron; Margaret A. Fischl; Robert L. Murphy; Kenneth Fife; Janine Maenza; Mary E. Rosandich; et al.AIDS. 1999;13(6):685-694.
Appears in this Document